Galeterone
From Infogalactic: the planetary knowledge core
File:Galeterone.svg | |
Systematic (IUPAC) name | |
---|---|
17-(1H-benzimidazol-1-yl)androsta-5,16-dien-3β-ol
|
|
Clinical data | |
Routes of administration |
Oral |
Identifiers | |
CAS Number | 851983-85-2 |
PubChem | CID: 11188409 |
ChemSpider | 9363493 |
UNII | WA33E149SW |
KEGG | D10125 |
Chemical data | |
Formula | C26H32N2O |
Molecular mass | 388.25 |
|
|
|
Galeterone (TOK-001 or VN/124-1) is a novel steroidal antiandrogen under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique dual mechanism of action, acting as both an androgen receptor antagonist and an inhibitor of CYP17A1, an enzyme required for the biosynthesis of the androgens.[1] It shows selectivity for 17,20-lyase over 17-hydroxylase.[2]
As of 2016, galeterone is being compared to enzalutamide in a phase III clinical trial (ARMOR3-SV) for AR-V7-expressing metastatic castration-resistant prostate cancer.[3][4]
See also
References
Categories:
- Pages with broken file links
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Drugboxes with an unspecified ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Articles that show a Medicine navs template
- Antiandrogens
- Enzyme inhibitors
- Experimental cancer drugs
- Steroids